The Defense Department is betting $224 million that Columbia-based Osiris Therapeutics? patented stem cells can reduce gastrointestinal damage caused by exposure to a radiological weapon.

Osiris? contract with the department will enable the company to develop and stockpile its adult stem cell therapy, Prochymal, to reduce damage from radiation exposure from “dirty” bombs or other weapons.